Skip to main content
KWANGDONG PHARMACEUTICAL CO.,LTD logo

KWANGDONG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 009290 ISIN · KR7009290008 KO Manufacturing
Open in API
Filings indexed 280 across all filing types
Latest filing 2025-06-26 Major Shareholding Noti…
Country KR South Korea
Listing KO 009290

About KWANGDONG PHARMACEUTICAL CO.,LTD

https://eng.ekdp.com/

Kwangdong Pharmaceutical is a human healthcare company that develops, manufactures, and sells a diverse range of products, including pharmaceuticals and health-oriented beverages. Founded on the principle of the 'scientification of Oriental medicine,' the company integrates traditional Korean medicinal concepts with modern Western science. Its portfolio includes Over-the-Counter (OTC) and prescription (ETC) drugs, general health supplements, and traditional health foods. The company is also prominent in the consumer market with its popular beverage lines, featuring well-known products such as the Vita 500 vitamin drink and Corn Silk Tea. Additionally, Kwangdong is involved in the distribution of mineral water.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (pledges) of major shareholders and their special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-06-26 Korean
풍문또는보도에대한해명(미확정)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing from Kwangdong Pharmaceutical addressing market rumors regarding their contract for 'Samdasoo' water distribution. It is a standard 'Clarification of Rumors or Reports' filing submitted to the Korea Exchange (KRX). Since it does not fit into specific categories like financial reports, M&A, or director dealings, and serves as a general regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2025-06-26 Korean
기업지배구조보고서공시
Governance Information Classification · 100% confidence The document is a 'Corporate Governance Report' (기업지배구조보고서) for Kwangdong Pharmaceutical. It details the company's governance structure, shareholder rights, board composition, and compliance with governance indicators. This type of report is a standard regulatory filing in South Korea, specifically categorized under 'Corporate Governance Report' (CGR) in the provided schema, as it focuses on internal rules, board structure, and governance practices.
2025-05-30 Korean
풍문또는보도에대한해명(미확정)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from Kwangdong Pharmaceutical regarding a media report about their 'Samdasoo' water distribution contract. It is a standard 'Clarification of Rumors or Reports' filing, which is a common regulatory requirement in the Korean stock market (KRX). Since it does not fit into specific categories like M&A, financial reports, or dividends, and serves as a general regulatory announcement, it is classified as a Regulatory Filing (RNS).
2025-05-29 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Kwangdong Pharmaceutical, covering the period from January 1, 2025, to March 31, 2025. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Kwangdong Pharmaceutical. It provides a summary table of key financial metrics (revenue, operating profit, net income) for the first quarter of 2025 compared to previous periods. It is a short, structured announcement of preliminary financial results, which fits the definition of an Earnings Release (ER). Q1 2025
2025-05-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.